Allos would like to request redaction addition of clarification in the FDA Briefing Document to the Oncologic Drugs Advisory Committee on NDA[removed]in the following sections: - Amgen - Document - PDFSEARCH.IO

First Page	Meta Content
	Allos would like to request redaction addition of clarification in the FDA Briefing Document to the Oncologic Drugs Advisory Committee on NDA[removed]in the following sections: Add to Reading List Open Document File Size: 62,26 KB Share Result on Facebook Company Denosumab Amgen Inc. / / MedicalCondition solid tumors / metastases / osteoporosis / bone metastases / / Organization FDA Briefing Document Pediatric Oncology Subcommittee / U.S. Food and Drug Administration / Oncologic Drugs Advisory Committee / / SocialTag Health Bone Medicine Pharmaceutical industry Amgen Denosumab Osteoporosis

Allos would like to request redaction addition of clarification in the FDA Briefing Document to the Oncologic Drugs Advisory Committee on NDA[removed]in the following sections:Add to Reading List